NOVO.B.DK

243.4

-3.51%↓

HLUNB.DK

39.42

+1.39%↑

AMBUB.DK

78.6

-0.19%↓

NOVO.B.DK

243.4

-3.51%↓

HLUNB.DK

39.42

+1.39%↑

AMBUB.DK

78.6

-0.19%↓

NOVO.B.DK

243.4

-3.51%↓

HLUNB.DK

39.42

+1.39%↑

AMBUB.DK

78.6

-0.19%↓

NOVO.B.DK

243.4

-3.51%↓

HLUNB.DK

39.42

+1.39%↑

AMBUB.DK

78.6

-0.19%↓

NOVO.B.DK

243.4

-3.51%↓

HLUNB.DK

39.42

+1.39%↑

AMBUB.DK

78.6

-0.19%↓

Search

Coloplast A-S (Class B)

Fermé

490.5 1.78

Résumé

Variation du prix de l'action

24h

Actuel

Min

481.7

Max

494.8

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

27.421

110.024

BPA

6.32

Rendement du dividende

4.84

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.84%

2.26%

Prochains Résultats

12 mai 2026

Date du Prochain Dividende

20 mai 2026

Date du Prochain Détachement de Dividende

18 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-9.1B

110B

Ouverture précédente

488.72

Clôture précédente

490.5

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 févr. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 févr. 2026, 22:36 UTC

Résultats

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 févr. 2026, 22:32 UTC

Résultats

Woodside Energy Fiscal Year Net Profit Falls 24%

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 févr. 2026, 23:58 UTC

Market Talk
Résultats

Global Energy Roundup: Market Talk

23 févr. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 févr. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 févr. 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Crescent Capital Partners Owns 53% of ClearView Wealth

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 févr. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 févr. 2026, 23:40 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 févr. 2026, 23:39 UTC

Acquisitions, Fusions, Rachats

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 févr. 2026, 23:31 UTC

Résultats

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 févr. 2026, 23:28 UTC

Résultats

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 févr. 2026, 23:27 UTC

Résultats

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 févr. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 févr. 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 févr. 2026, 22:31 UTC

Résultats

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 févr. 2026, 22:24 UTC

Résultats

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy FY Underlying Ebitda A$700.9 Million

23 févr. 2026, 22:22 UTC

Résultats

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 févr. 2026, 22:21 UTC

Résultats

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 févr. 2026, 22:20 UTC

Résultats

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat